Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Reports Improved Quarter, Again

publication date: May 28, 2008

WuXi PharmaTech Inc. reported Q1 revenues were 69% higher than year-earlier numbers at $57.1 million. However, this year’s revenue includes an $11 million contribution from the AppTec acquisition, which was closed on January 31, 2008. Without AppTec, WuXi’s revenues grew by 36%. Net income jumped 132% to $13.9 million, which works out to an earnings per ADS figure of 19 cents. WuXi reiterated its guidance of 2008 revenues in a $280 million-$300 million range. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital